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Poster Session II 111Conditioning was TBI-based in 80/81 pts and GVHD prophylaxis
was with Cyclosporine and short-course Methotrexate (MTX) (15
mg/m2 d 1 1 and 10 mg/m2 d 1 3, d 1 6 and d 1 11). Fifty of
81 pts received.80% of the planned MTX dose. Forty three pts re-
ceived SCT from a 10/10 high-resolution HLA-matched donor, 25
pts received a 1-antigen mismatched SCT, 12 pts received a 2-anti-
gen mismatched SCT and 1 pt a 3-antigen mismatched SCT. The
donor was male for 68 pts and female for 13 pts. Median CD 34 cell
dose was 7.75  106 (range-9.46  104–33.6  106)/kg. Results:
The estimated 3-year NRM, RR and OAS were 39% (95%CI
25%-50%), 30% (95%CI 17%-41%) and 43% (95%CI 31%-
58%), respectively. In multivariate analysis, CD 34 cell dose
.7.75  106/kg was associated with faster neutrophil engraftment,
p\0.001 and reduced NRM (28% vs. 49%, p5 .019), but did not
influence the incidence of either acute or chronic GVHD or OAS.
On multivariate analysis the most important predictor of reduced
grade 3–4 acute GVHD (22% vs. 49%, p 5 .005), NRM (30 vs.
65%, p5 .006), and improved OAS (50% vs. 24%%) was adminis-
tration of .80% of the planned MTX dose. Conclusion: A higher
CD34 cell dose in unrelated donor SCT does not adversely influ-
ence the incidence of GVHD and is associated with faster neutro-
phil engraftment and a reduction in NRM. Delivery of at least
80% of the planned short-course MTX GVHD prophylaxis con-
tinues to be critical in producing a favourable outcome.299
THE RELATION BETWEEN THE FREQUENCY OF PRESENCE OF THROM-
BOPHILIA AND THROMBOEMBOLIC COMPLICATIONS AFTER ALLOGE-
NEIC HEMATOPOIETIC CELL TRANSPLANTATION (AHCT)
Topcuoglu, P., Gunaltay, S., Dalva, K., Bilgin, A.U., Arat, M.,
Ozcan, M. Ankara University, Ankara, Turkey.
Venous thromboembolism (TE) occurs as a consequence of ge-
netic and environmental factors. Important genetic risk factors are
deficiencies of natural anticoagulants, antithrombin-III (AT-III),
protein C (PC) and PS, and genetic mutations of factor V leiden
(FVL) and prothrombin (PTH A20210). Thrombotic complica-
tions after HCT are usually catheter-related thrombosis (CRT),
pulmonary TE (PTE) and deep vein thrombosis (DVT). Our aim
in this study was to evaluate the effects of the deficiencies of ATIII,
PC and PS, and the gene mutations of FVL and PTH on the inci-
dence of the development of TE complications and liver sinusoidal
obstruction syndrome (SOS) at the early or late period post-HCT.
In our center, pre-transplant work-up includes routine thrombo-
philia tests. Between Apr 1999-Jan 2007 260 patients (M/F: 145/
115, median age: 34 years) admitted to our transplantation center
were retrospectively analyzed for the relation of the presence of
thrombophilia and the frequencies of the occurrence of a TE com-
plications and liver SOS. All but 6 patients (n5 254) underwent al-
logeneic HCT from an HLA identical sibling donor. The ratios of
the detection of the plasma activation level below 50% for PC, PS
and AT-III were 5.8% (12/206), 15.7% (32/204) and 25.4% (66/
260), respectively. Gene mutations were studied in 198 patients
prior to transplant and the frequencies of gene mutations were de-
tected in 11.6% patients (n5 23) either FVL (n5 14) or PTH (n5
9) gene. None of the patients had both mutations, FVL and PTH.
At the peri- or post-transplantation period we observed venous TE
in 24 patients (17 CRT, 2 PE and 5 DVT), liver SOS in 23 patients
and myocard infarction at the early period in only one patient. In 4
out of 12 patients with low PC activity CRT occurred, and liver
SOS was observed in only one patient. In 6 out of 24 patients
with genetic mutation developed a TE complication, 5 CRT and
1 PTE. CRT occurred in 4 of 14 patients with FVL mutation, while
1 CRT and 1 PTE among 9 patients with PTH mutation were ob-
served. Liver SOS was seen in only one patient with PTH heterozy-
gote positive. We found the presence of low PC level or genetic
mutation increased the frequency of the development of TE (OR:
6.9 and 3.7, respectively), but no effect on the liver SOS. In conclu-
sion, the use of thromboprophylaxis at peri-transplant period in pa-
tients with genetic mutations is still a controversial topic; which
should be elucidated with controlled studies.300
ONCE DAILY BUSULFAN CYCLOPHOSPHAMIDE IS WELL TOLERATED
AND EFFECTIVE PRIOR TO ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANTATION
LeMaistre, J., Bachier, C., Smith, B., LeMaistre, C.F., Shaughnessy, P.J.
Texas Transplant Institute, San Antonio, TX.
Intravenous busulfan (Bu) allowes for the delivery of Bu in one
dose instead of dividing 4 times per day. Pharmacokinetic (PK)
studies of Bu support the feasibility of once daily dosing, and prior
clinical studies found no unexpected toxicity of once daily Bu when
combined with fludarabine. Based on this data we began an institu-
tional protocol of delivering Bu once daily follwed by standard cy-
clophosphamide (CY) and allogeneic hematopoietic stem cell
transplantation (HCT). We report a retrospective review of our in-
stitutional data using once daily BuCY vs 4 daily BuCY and total
body irradiation (TBI)/CY in pts who received allogeneic HCT
from January 2000 to December 2006. Bu 3.2 mg/kg daily  4
days followed by CY 60 mg/kg daily  2 days was given to 42 pa-
tients (pts). Bu 0.8 mg/kg given 4 daily for 4 days followed by
CY 60 mg/kg was given to 15 pts. CY 60 mg/kg daily for 2 days
and fractionated TBI 1200 cGy delivered over 3 days was given to
60 pts. All donors were HLA matched at A, B, C, DR, and DQ
and were related/unrelated in 23/19, 11/4, and 21/39 in the once
daily BuCY, 4 daily BuCY, and TBI/CY, respectively. Signifi-
cantly more pts with myeloid leukemias received a BuCY regimen
and significantly more pts with lymphoid malignancies received
TBI/CY. Median follow up for all pts was 370 days. VOD devel-
oped in 2 pts in the once daily BuCY group, 1 pt in the 4 daily
BuCY group, and in no pts in the TBI/CY group. Acute GVHD
grade II-IV occured in 33% of the once daily BuCY pts, 53% of
the 4 daily BuCY pts, and 32% of the TBI/CY pts. Estimated ac-
tuarial transplant related mortality (TRM) and survival are de-
scribed in the table below. There was no statistical difference in
TRM or survival between the once daily and 4 daily BuCY groups
or the total BuCY group and TBI/CY group. The once daily BuCY
group had significantly less TRM than the TBI/CY group at 100
days (p5 0.04) and at 1 year (p5 0.01). The once daily BuCY group
also had significantly better survival at one year compared to the
TBI/CY group (p 5 0.01), but this became non-significant at 3
years. The significant differences in the pt populations treated in
the BuCY and TBI/CY groups, as well as the retrospective nature
of this study, limit the ability to draw conclusions comparing the
groups. However, this review does demonstrate once daily BuCY
and allogeneic HCT is well tolerated with no unexpected TRM,
and provides good long term survival in pts with myeloid malignan-
cies.Survival and TRM
1  BuCY 4  BuCY CY/TBI
(95%CI) (95%CI) (95%CI)100 day TRM 7% (1–16) 21% (7–51) 22% (15–35)
1 year TRM 21% (11–38) 37% (17–69) 45% (33–59)
1 year Survival 70% (53–82) 47% (21–69) 49% (35–61)
3 year Survival 43% (24–59) 27% (8–50) 37% (24–49)301
THE IMPACT OF THE DISPARITIES OF SHORT TANDEM REPEATS (STR)
BETWEEN DOONOR-RECIPIENT PAIR ON THE ALLOGENEIC HEMATO-
POIETIC CELL TRANSPLANTATION (AHCT) OUTCOME
Serbest, E., Topcuoglu, P., Dalva, K., Bilgin, A.U., Soydan, E.A.,
Ozcan, M., Arslan, O., Ilhan, O., Beksac, M., Gurman, G., Arat, M.
Ankara University, Ankara, Turkey.
STR marker systems are used in the monitoring of hematopoietic
chimerism in patients after AHCST. The biological effect of STR
disparity on AHCT outcome has rarely been studied. Therefore,
we aimed to evaluate the impact of STR disparity on allo-HCT out-
come in our single center. Between Sept 2001 and Feb 2007, 150 pa-
tients (81M/69F, median age: 34 ys) underwent AHCT (Stem cell
112 Poster Session IIsource: 119 PB/31 BM) were retrospectively analyzed. Their diag-
noses were 90 acute leukemia, 30 CML, 6 MDS and 24 other dis-
eases. Multiplex PCR method was performed to amplify 16 STR
loci (D3S1358, HUMvWA, D16S539, D2S1338, Amelogenin,
D8S1179, D21S11, D18S51, D19S433, THO1, FGA, D7S820,
CSF1PO, D13S317, TPOX, D5S818) (ABI Prism 3130). The loci
examined were classified as complete matched (CM), partially
matched (PM), and fully mismatched (FMM) between donors and
recipients.
Results: The loci of D13S317, D18S51 and D2S1338 were the
most informative, while the loci of TPOX and CSF1PO were the
least. The incidence of acute GvHD was 46.7% (n 5 69), which
acute severe GvHD (grII-IV) was observed in only 31 patients.
Chronic GvHD was developed in 63.4% patients. The incidence
of grII-IV GvHD was higher in patient with CM in TPOX loci
(p 5 0.02). Chronic GvHD was more frequent in the patients
with PM in D5S818 loci than those with CM or MM (p 5 0.016).
While PM D21S11 increased TRM, MM or PM in D5S818 loci de-
creased the TRM. In our cohort analysis, 2-year probability of dis-
ease-free survival(DFS) and overall survival(OS) were 58.1 6 5.5%
and 67.56 4.4%, respectively. The CM in D21D11 locus (p5 0.07)
and PM in D5S818 locus (p 5 0.009) prolonged the probability of
DFS. In multivariate analysis, these loci had an impact on DFS (p5
0.055 ve p5 0.005). D19S433 and D5S818 loci had an effect on the
OS. We repeated similar analyses into two groups, mismatched
(MM) group, which FMM and PM was accepted as a whole group
or CM group, while the incidence of grII-IV GvHD was higher
in patients with CM of D18S51 and TPOX loci, the chronic
GvHD was more frequent in those with CM D5S820 loci. Similar
as the first analyses MM in D21S11 and CM in D5S818 affected
both TRM and DFS. Besides, MM in FGA locus decreased TRM
and prolonged DFS. The impact of D5S818 on the OS also contin-
ued, additionally D19S433 had minimal effect on the OS. In conclu-
sion, some disparities of STR loci might affect the transplantation
outcome; however, these results should be analyzed together with
other co-variates and on multicenter basis.302
AN EVALUATION OF DNA METHYLATION CHANGES IN A PHASE I CLIN-
ICAL TRIAL OF LOW-DOSE 5-AZACITIDINE (AZA) GIVEN AS MAINTE-
NANCE THERAPY AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANTATION (HSCT)
Silva, L.1, Garcia-Manero, G.2, Giralt, S.1, McCormick, G.1,
Soriano, A.2, Champlin, R.1, Kantarjian, H.2, de Lima, M.1. 1 The Uni-
versity of Texas MD Anderson Cancer Center, Houston, TX; 2 The Uni-
versity of Texas MD Anderson Cancer Center, Houston, TX.
DNA methylation of CpG Islands is a frequently found epige-
netic alteration in AML and MDS that leads to deranged gene activ-
ity. Inhibition of the enzyme DNA methyltransferase is associated
with hypomethylation, and possibly, restoration of normal function
to genes critical for differentiation and proliferation. AZA is a DNA
hypomethylating agent that may induce increased tumor immuno-
genicity, potentially magnifying the GVL effect. Lower doses are
likely to be better tolerated after HSCT and to be effective inducers
of hypomethylation. We hypothesized that AZA after HSCT will
lower relapse rates, and designed a phase I clinical trial that also
uses a molecular surrogate endpoint for dose finding. Here we de-
scribe methylation changes in patients so treated.
Pts with AML or high-risk MDS not in first remission (CR) are
eligible. Three doses of AZA were studied: 8, 16, and 24 mg/m2
daily  5 starting on day 1 42. DNA was extracted from mononu-
clear cells of 22 pts that received AZA. The methylation status of
long interspersed nuclear elements (LINE) was analyzed by pyrose-
quencing as a surrogate marker of global DNA methylation before
and after AZA administration. Gene specific methylation changes
were studied using a methylated CpG island amplification(MCA)/
CpG array.
Median age was 57 years. Diagnoses were MDS (n 5 4) and
AML(n5 18). Disease status at HSCT: CR, 18% (n5 4), and active
disease, 82%(n 5 18). LINE methylation results were as follows:
baseline: 44.51%; on cycle 1, 5th day of AZA: 24 mg/m2 5
43.58%; 16 mg/m2: 36.93%; 8 mg/m2: 42.86%. Two pts have re-lapsed while on AZA. There has been no major drug-related toxicity
and no increase in GVHD incidence. Analysis of gene-specific
methylation is ongoing.
AZA in doses up to 24 mg/m2 can be safely administered early af-
ter HSCT. Given the lack of toxicity and low levels of changes in
DNA methylation observed, we are currently investigating higher
doses.303
ROLE OF EXTENSIVE SPLENOMEGALY IN PATIENTS WITH MYELOFI-
BROSIS UNDERGOING A REDUCED INTENSITY ALLOGENEIC STEM
CELL TRANSPLANT
Ciurea, S.O.1, Sadegi, B.1, Wilbur, A.1, Alagiozian-Angelova, V.1,
Gaitonde, S.1, Dobogai, L.1, Akard, L.P.2, Hoffman, R.3,4,
Rondelli, D.1,4. 1 University of Illinois at Chicago, Chicago, IL; 2 Indiana
Blood and Marrow Transplantation Program, Indianapolis, IN; 3 Mount
Sinai School of Medicine, New York, NY; 4 Myeloproliferative Disorder-
Research Consortium.
Allogeneic stem cell transplantation has been shown to restore
normal hematopoiesis in patients with intermediate or high risk pri-
mary myelofibrosis (PMF) or myelofibrosis preceeded by polycy-
themia vera or essential thrombocythemia. However, in patients
with PMF and extensive splenomegaly it is not clear whether trans-
plant is associated with an unacceptable risk or if splenectomy
should be performed prior to transplant. In this study, ten consec-
utive patients with myelofibrosis who were not splenectomized re-
ceived an allogeneic hematopoietic stem cell transplantation
(HSCT) from related or unrelated donors and were periodically
monitored by ultrasound or CT scan for 12 months after transplant
to assess the kinetics of the reduction of splenomegaly. These find-
ings were correlated with the time to resolution of marrow fibrosis,
time to engraftment and clinical outcome. Over a 12 month period
a progressive reduction in spleen size was observed in all the patients
and paralleled the reduction in marrow fibrosis. Of 10 patients, 5
with a splenic longitudinal diameter .30 cm showed a more pro-
longed time to engraftment ANC . 0.5  109/L (d 19 6 5 vs 13
6 2, p 5 0.05) and platelet . 20  109/L (d 75 6 104 vs 11 6 2,
p 5 0.06). However, of the 5 patients with more extensive spleno-
megaly only 2 experienced delayed engraftment of platelets (d 77
and 256, respectively). Full donor chimerism was observed in all pa-
tients within 60 days after transplantation regardless of the size of
the spleen. At a median follow-up of 51 months (range: 2–81) all
the patients are alive but 1 who died of a TTP like syndrome 2
months after transplant and had a small spleen at the time of trans-
plant. A clinical CR has been documented in 7 patients and 2 have
achieved clinical improvement according to to the criteria estab-
lished by the International Working Group for Myelofibrosis Re-
search and Treatment (IWG-MRT). These findings suggest that
allogeneic HSCT with RIC regimen can be safely performed in pa-
tients with extensive splenomegaly. Although in these patients the
time to achieve a full hematopoietic engraftment may be prolonged,
the significant risk of morbidity and mortality associated with sple-
nectomy may be avoided.304
EFFECT OF SUBSTITUTING FLUDARABINE AND THYMOGLOBULIN FOR
CYCLOPHOSPHAMIDE IN BUSULFAN-BASED CONDITIONING REGIMENS
ON T-CELL CHIMERISM AND OUTCOMES AFTER ALLOGENEIC HEMATO-
POIETIC CELL TRANSPLANTATION (HCT)
O’Donnell, P.V.1, Woolfrey, A.E.1, Storer, B.1, Sorror, M.L.1,
Furlong, T.1, Anasetti, C.2, Heimfeld, S.1, Flowers, M.1,
Appelbaum, F.R.1, Martin, P.J.1, Deeg, H.J.1. 1 Fred Hutchinson Cancer
Research Center, Seattle, WA; 2 H. Lee Moffitt Cancer Center, Tampa,
FL.
Substitution of cyclophosphamide by agents such as fludarabine
and thymoglobulin in busulfan-based conditioning regimens has
been used to reduce complications after allogeneic HCT. We per-
formed a retrospective analysis of outcomes among 348 patients
